Point being is that you need to do the math/financing before you make a judgement call to let warrants expire worthless. It makes sense for management to be more transparent and get the PPS up to get warrants exercised. We have been delayed again and will need money. The recent capital raises at these low prices makes me think that it was out of desperation or at the least, not planned for. If we had a huge buyout deal or collaboration for example with Verb then we would not be at these PPS levels. If there is a money partner to get us through projected FDA approval anticipated mid 2018 then it is not being reflected in the stock price. There is a lot of cash burn between now and approval. I don't understand this level of "secrecy" between Titan and whatever companies they are working with.
News 
Market Data 
Discover 
AI
